BRCA1 and ovarian cancer: Patients who presented BRCA1/2 mutations presented a greater benefit from dose-dense than wild-type patients, as well as patients with positive family history for breast or ovarian cancer presented a greater benefit from dose-dense than patients who did not have family history of breast or ovarian cancer (Fig. 4).